- Home
- OPCH vs AAPG Comparison
OPCH vs AAPG Comparison
Compare OPCH & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPCH
- AAPG
- Stock Information
- Founded
- OPCH N/A
- AAPG 2009
- Country
- OPCH United States
- AAPG China
- Employees
- OPCH N/A
- AAPG N/A
- Industry
- OPCH Medical/Nursing Services
- AAPG Biotechnology: Pharmaceutical Preparations
- Sector
- OPCH Health Care
- AAPG Health Care
- Exchange
- OPCH Nasdaq
- AAPG Nasdaq
- Market Cap
- OPCH 4.4B
- AAPG 3.6B
- IPO Year
- OPCH N/A
- AAPG 2025
- Fundamental
- Price
- OPCH $28.99
- AAPG $32.51
- Analyst Decision
- OPCH Buy
- AAPG Strong Buy
- Analyst Count
- OPCH 8
- AAPG 3
- Target Price
- OPCH $34.88
- AAPG $49.00
- AVG Volume (30 Days)
- OPCH 2.5M
- AAPG 7.8K
- Earning Date
- OPCH 10-30-2025
- AAPG 11-19-2025
- Dividend Yield
- OPCH N/A
- AAPG N/A
- EPS Growth
- OPCH 6.77
- AAPG N/A
- EPS
- OPCH 1.27
- AAPG N/A
- Revenue
- OPCH $5,530,491,000.00
- AAPG $54,524,554.00
- Revenue This Year
- OPCH $14.96
- AAPG N/A
- Revenue Next Year
- OPCH $7.74
- AAPG $368.64
- P/E Ratio
- OPCH $22.87
- AAPG N/A
- Revenue Growth
- OPCH 15.79
- AAPG N/A
- 52 Week Low
- OPCH $21.39
- AAPG $16.50
- 52 Week High
- OPCH $35.53
- AAPG $48.45
- Technical
- Relative Strength Index (RSI)
- OPCH 60.94
- AAPG 46.17
- Support Level
- OPCH $26.70
- AAPG $30.93
- Resistance Level
- OPCH $29.23
- AAPG $34.31
- Average True Range (ATR)
- OPCH 1.11
- AAPG 0.85
- MACD
- OPCH 0.21
- AAPG 0.17
- Stochastic Oscillator
- OPCH 93.29
- AAPG 66.29
About OPCH Option Care Health Inc.
Option Care Health Inc is the provider of home and alternate-site infusion services. It provides treatment for bleeding disorders, neurological disorders, heart failure, anti-infectives, and chronic inflammatory disorders among others.
About AAPG Ascentage Pharma Group International American Depository Shares
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.